Minerva Neurosciences | NERV - Interest Expense On Debt


Minerva Neurosciences reported $2.31M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Adma Biologics USD 3.42M 1.32M Jun/2026
ALKERMES USD 27.55M 1.63M Sep/2026
AstraZeneca USD 371M 31M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Cipla INR 167.4M 2.9M Sep/2026
Compugen USD 1.84M 485K Jun/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 316M 201.3M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Takeda JPY 63.38B 466M Sep/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025